IMF Videos Search Content For Healthcare Professional (78) Healthcare Provider (77) Care Partner (68) Patient (68) Series - Any - ASCO/EHA (32) ASH (30) Ask Dr. Durie (16) Community Workshops (3) Emerging Therapies (12) Facebook Live (6) Health Equity (4) IMWG (3) Living Well with Myeloma (3) Myeloma in a Minute (2) Myeloma Made Simple (6) Myeloma University (9) Q&A (7) Recent News and Developments (2) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (186) Financial Considerations (15) Frontline Therapy (84) Health Equity (34) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (72) Lifestyle (47) Mental & Emotional Health (29) Myeloma 101 (59) Myeloma in the News (8) Public Policy & Advocacy (17) Q&A's (43) Recorded Seminars & Workshops (15) Recorded Webinars (24) Relapse/Refractory Myeloma (138) Research Updates (194) Symptom Management (115) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (90) High-Risk Myeloma (40) High-risk Smoldering Myeloma (19) Late Relapse (4–6 Lines of Therapy) (103) MGUS (8) Newly Diagnosed (Pre-Treatment or First Treatment) (26) Smoldering Myeloma (16) Types of Therapy Immunomodulatory drugs (IMiDs) (33) Immunotherapies (CAR T; BiTE, etc.) (100) Monoclonal antibodies (35) Proteasome inhibitors (25) Stem cell transplant (26) Steroids (20) Supportive Care (37) Year Published 2026 (21) 2025 (22) 2024 (35) 2023 (39) 2022 (4) 2021 (4) 2020 (3) 2019 (2) 2018 (1) 2017 (1) 2016 (4) 2015 (2) Trusted Voices Dr. Joseph Mikhael (35) Dr. Brian GM Durie (15) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (6) Donna Catamero, ANP-BC, OCN, CCRC (3) Dr. María-Victoria Mateos (2) Dr. Saad Usmani (2) Dr. Sagar Lonial (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Myeloma Made Simple: Bispecific Antibodies Made Simple | Bispecific Antibodies for Myeloma Treatment May 29, 2024 Myeloma Made Simple Myeloma Made Simple: Xpovio (Selinexor) Made Simple | Selinexor for Multiple Myeloma Treatment May 15, 2024 Myeloma Made Simple What should be done if a patient relapses while in a clinical trial? April 19, 2024 Ask Dr. Durie What concerns about the early use of CAR-T therapy were addressed in the ODAC hearing? April 4, 2024 Ask Dr. Durie What are considerations for myeloma patients regarding immune therapy targets, side effects, and monitoring? March 21, 2024 Ask Dr. Durie Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma February 22, 2024 ASH Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) February 15, 2024 ASH Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial February 15, 2024 ASH BCMAxCD3 Bispecific Antibody Elranatamab Is Effective in Patient Myeloma Relapsed after BCMA CAR-T January 25, 2024 ASH Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study January 12, 2024 ASH Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3 January 12, 2024 ASH Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose January 11, 2024 ASH Load More
